Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6338345 | 0.92 | NQO2 (0.46) | NQO2MEN1KMT2ALRRK2MAPT | |
| SCHEMBL11215523 | 0.73 | NQO2 (0.59) | NQO2MEN1KMT2AMAPTCHRNB2 | |
| SCHEMBL6347633 | 0.68 | PTPN1 (0.32) | KMT2AMAPTPGRTDP1 | |
| SCHEMBL6988776 | 0.66 | NQO2 (0.51) | NQO2MEN1KMT2AMAPTTP53 | |
| SCHEMBL357999 | 0.64 | MEN1 (0.71) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL10059474 | 0.63 | GAA (0.53) | NQO2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL10079113 | 0.62 | FYN (0.45) | MEN1KMT2AMAPTSMN1; SMN2NOX4 | |
| SCHEMBL18682061 | 0.62 | CHRNB2 (0.57) | MEN1KMT2AMAPTTP53TDP1 | |
| SCHEMBL11234944 | 0.60 | SMN1; SMN2 (0.63) | MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6815121 | 0.59 | ALDH1A1 (0.70) | MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930124-B2 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | AVENTIS PHARMA S. A. (FR) | 2005-08-16 | — | — | US | claimed |
| US-20040082645-A1 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | AVENTIS PHARMA S.A. (FR) | 2004-04-29 | — | — | US | claimed |
| US-6930124-B2 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | AVENTIS PHARMA S. A. (FR) | 2005-08-16 | — | — | US | disclosed |
| US-20040082645-A1 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | AVENTIS PHARMA S.A. (FR) | 2004-04-29 | — | — | US | disclosed |
| EP-1370555-A1 | COMPOUNDS DERIVED FROM OXINDOLES AND THE USE THEREOF IN CANCEROLOGY | Aventis Pharma S.A. (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002072575-A1 | COMPOUNDS DERIVED FROM OXINDOLES AND THE USE THEREOF IN CANCEROLOGY | AVENTIS PHARMA S.A. (FR) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082645-A1 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | TUBB1, TUBB3, TUBA1C | NQO2 806/4885MEN1 1742/4885KMT2A 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.